Health - Fourth Report
Here you can browse the report together with the Proceedings of the Committee. The published report was ordered by the House of Commons to be printed 22 March 2005.
Contents
Terms of Reference
REPORT
Summary
1 Introduction
2 The UK pharmaceutical industry
Medicines and health gains
Generic medicines
The Pharmaceutical Industry Competitiveness
Task Force
3 Difficulties facing the pharmaceutical
industry
4 From drug development to prescription
Drug development and the conduct of medical
research
Medicines licensing
Post-licensing evaluation, including value
for money assessments
The provision of medicines information
Information to prescribers
Information to patients
Professional and patient education
The promotion of drugs
5 Arrangements for controlling the activity
of the UK-based pharmaceutical industry
International standards and 'good clinical
practice' guidelines
Research Ethics Committees
Licensing: the MHRA
Post-licensing surveillance
Orphan drugs
The National Institute for Clinical Excellence
The Pharmaceutical Price Regulation Scheme
Drug and Therapeutics Committees
Professional bodies
The industry's codes of practice
6 Control of access to medicines
Prescribing
Doctors
Nurses
Pharmacists
7 Inappropriate level of industry influence?
8 Influence of the industry on key groups
Research into pharmaceuticals
Innovation and therapeutic advance
Conduct of medical research
Prescribers
The use of journals
Drug company promotional activities
Promotional campaigns: targeting of healthcare
professionals
Advertising
Patients
Information to patients: the Internet and
PILs
Disease awareness campaigns
Promotional campaigns: targeting patients
and the general public
Patient organisations
The drug regulatory system
Reputation of the regulator
Post-marketing surveillance
The patient voice
Expert Working Group report on SSRI safety
Wider significance of the SSRI experience
Medicines reclassification
NICE
Government
9 Conclusions and recommendations
Unsafe use of drugs
Medicalisation of society: 'a pill for every
ill'
Recommendations
The industry
The regulatory system
Medical practitioners
Patients
NICE
Government and EU
Annex: contributions from pharmaceutical
companies to All-Party Groups
List of Abbreviations
Glossary
Conclusions and recommendations
Formal minutes
Witnesses
Reports from the Health Committee since 2001
MINUTES OF EVIDENCE - VOLUME II (HC 42-II)
WRITTEN EVIDENCE - VOLUME II (HC 42-II)
| 
